600201 Jinyu Bio-Technology
- 8.05
- -0.89-9.96%
Jinyu Bio-Technology News
China Issues Temporary Approval for Jinyu's Inactivated Bovine Nodular Dermatosis Vaccine
China's agriculture ministry issued a temporary approval to Jinyu Bio-Technology (SHA:600201) subsidiary Jinyu Baoling Biopharmaceutical's inactivated bovine nodular dermatosis vaccine indicated for c
Calculating The Fair Value Of Jinyu Bio-technology Co., Ltd. (SHSE:600201)
Key Insights Jinyu Bio-technology's estimated fair value is CN¥8.59 based on 2 Stage Free Cash Flow to Equity With CN¥10.09 share price, Jinyu Bio-technology appears to be trading close to its estim
Biology Co., Ltd. (600201.SH): Jointly established “Inner Mongolia Centennial Synthetic Biotechnology Co., Ltd.” with leading domestic research teams
Gelonghui, May 9 | Biotech Co., Ltd. (600201.SH) said on the interactive platform that in 2023, the company will “take the lead in entering the era of innovative synthetic biology integrating biotechnology and information technology; advance into multiple multivalent vaccines, iterative vaccines, digital vaccines and novel drugs to overcome the 100-year challenge of the African swine fever vaccine; apply AI intelligence to provide the aquaculture industry with overall solutions for epidemic prevention and control, and use value marketing to improve quality and efficiency for users” as the company's development strategy. As a path support for achieving strategic goals, the company and leading domestic research teams jointly established “Inner Mongolia Centennial Synthetic Biotechnology Co., Ltd.” This creation
Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Just Slashed This Year's Estimates
The analysts covering Jinyu Bio-technology Co., Ltd. (SHSE:600201) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year.
Biotech Co., Ltd. (600201.SH) announced first-quarter results, net profit of 106 million yuan decreased by 1.05% year-on-year
Biotech Co., Ltd. (600201.SH) released its report for the first quarter of 2024. The company achieved operating income of 3 during the reporting period...
Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Business Is Trailing The Market But Its Shares Aren't
With a price-to-earnings (or "P/E") ratio of 33.3x Jinyu Bio-technology Co., Ltd. (SHSE:600201) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E
Is The Market Rewarding Jinyu Bio-technology Co., Ltd. (SHSE:600201) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
With its stock down 14% over the past three months, it is easy to disregard Jinyu Bio-technology (SHSE:600201). It is possible that the markets have ignored the company's differing financials and de
Calculating The Intrinsic Value Of Jinyu Bio-technology Co., Ltd. (SHSE:600201)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Jinyu Bio-technology fair value estimate is CN¥6.57 With CN¥7.71 share price, Jinyu Bio-technology appears to be trading close to its estimat
Positive Earnings Growth Hasn't Been Enough to Get Jinyu Bio-technology (SHSE:600201) Shareholders a Favorable Return Over the Last Three Years
Jinyu Bio-technology Co., Ltd. (SHSE:600201) shareholders should be happy to see the share price up 15% in the last month. But that doesn't help the fact that the three year return is less impressi
Jinyu Bio-Technology Teams Up With RNA Cure to Develop MRNA Vaccine for African Swine Fever
Jinyu Bio-Technology (SHA:600201) collaborated with Shanghai-based RNA Cure to develop an mRNA vaccine against African swine fever, according to a filing on Friday. Through its wholly owned subsidiary
Biotech Co., Ltd. (600201.SH): Signed a cooperative development agreement for the African swine fever mRNA vaccine
On December 8, Gelonghui Biotech Co., Ltd. (600201.SH) announced that Jinyu Baoling Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently signed an “African swine fever mRNA vaccine cooperative development agreement” with Shanghai Blue Magpie Biomedical Co., Ltd. to jointly research and develop an African swine fever mRNA vaccine. mRNA vaccines have the advantages of rapid development, high safety, good immune protection effect, and high production efficiency. At present, they have become an important trend in the development of technology in the vaccine industry. The company and Blue Magpie Biotech launched a strategic cooperation in 2019 to build a “joint development of animal mRNA vaccines” platform, focusing on animal use
[BT Financial Report Instantaneous Analysis] Biotech Co., Ltd. 2023 Three-Quarter Report: Steady Growth in Performance, Increased Gross Margin
Jinyu Biotechnology Co., Ltd. (stock code: 600201), as a biotechnology corporation focusing on the manufacture of veterinary pharmaceuticals, occupies an important position in the veterinary biological products manufacturing industry. The company's main product is animal vaccines, which provide solid support for the development of animal husbandry and food safety and security. Under the dual impetus of large-scale farming and national policies, biotechnology shares are progressing steadily along the path of centralization, specialization, and standardization. In terms of assets and liabilities, the total assets of Biotech shares as of the end of the third quarter of 2023 reached 6.8 billion yuan, an increase of 6.42% over the 6.389 billion yuan at the end of the previous year. negative
While Institutions Invested in Jinyu Bio-technology Co., Ltd. (SHSE:600201) Benefited From Last Week's 7.1% Gain, Individual Investors Stood to Gain the Most
Key Insights Jinyu Bio-technology's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 25 shareholders own 42% o
Jinyu Bio-Technology's Unit Cattle Vaccine Passes Emergency Evaluation in China
Jinyu Bio-Technology (SHA:600201) unit Jinyu Baoling Biopharmaceutical will apply for temporary production of its bovine nodular dermatosis vaccine as the product passed China's emergency evaluation.
Bioscience (600201.SH): Bovine nodular skin disease inactivated vaccine passed emergency evaluation
Biology Co., Ltd. (600201.SH) issued an announcement. According to the “Regulations on the Administration of Veterinary Drugs”, “Veterinary Drug Registration Measures” and “Animal...
Is Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jinyu Bio-technology (SHSE:600201) has had a rough three months with its share price down 14%. It is possible that the markets have ignored the company's differing financials and decided to lean-in
Jinyu Bio-Technology Wins Nod to Market Veterinary Vaccine
Jinyu Bio-Technology (SHA:600201) obtained an approval from China's Ministry of Agriculture and Rural Affairs to market its live brucellosis vaccine for cattle and sheep. Brucellosis is caused by bruc
Bio Co., Ltd. (600201.SH): Subsidiary company obtains approval number for veterinary drug products
Gelonghui Co., Ltd. (600201.SH) announced that in accordance with the “Veterinary Drug Administration Regulations”, “Veterinary Drug Product Approval Number Management Measures” and other relevant regulations, and after review by the Ministry of Agriculture and Rural Affairs (“Ministry of Agriculture and Rural Affairs”) of the People's Republic of China (“Ministry of Agriculture and Rural Affairs”), the company's wholly-owned subsidiary, Jinyu Baoling Biopharmaceuticals Co., Ltd. (“Jinyu Baoling”) was authorized to produce an active brucellosis vaccine (Rev.1 strain) and issue a veterinary drug product approval number.
Jinyu Bio-Technology Registers Veterinary Vaccine For Sheep
Jinyu Bio-Technology (SHA:600201) has obtained a veterinary drug registration certificate for its Brucella Abortus live vaccine for sheep, according to a filing on Wednesday. The vaccine is intended t
Biology Co., Ltd. (600201.SH): The subsidiary obtained a new veterinary drug registration certificate
Gelonghui, September 5: Biology Co., Ltd. (600201.SH) announced that after review by the Ministry of Agriculture and Rural Affairs, the live brucellosis vaccine (Rev.1 strain) independently developed by Jinyu Baoling Biopharmaceuticals Co., Ltd., a wholly-owned subsidiary of the company, was approved as a new veterinary drug, and issued a “New Veterinary Drug Registration Certificate”. Brucellosis is a zoonotic chronic infectious disease caused by Brucella worldwide. Currently, the main strain of brucellosis prevalent in China is brucella sheep, positive sheep are the main source of brucellosis infection, and immunization through vaccine is an effective way to control brucellosis in sheep.
Analysis
Price Target
No Data
